Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

iGlarLixi CGM Study in Chinese T2D Individuals After OADs — Stella

Home/Type 2 Diabetes (T2D)/iGlarLixi CGM Study in Chinese T2D Individuals After OADs

View on ClinicalTrials.gov

Recruiting

Back to Type 2 Diabetes (T2D) trials

iGlarLixi CGM Study in Chinese T2D Individuals After OADs

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

China

Investigational Site Number: 1560001, Beijing

Key details

Phase

Post-approval study

Sponsor

Sanofi

Enrollment target

~678 participants

Started

December 2024

Primary completion

September 2026

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.